Cancer cells employ a unique defense mechanism to evade the effects of radiation treatment by exploiting an enzyme called Caspase-activated DNase (CAD). Removing CAD from cancer cells increases the effectiveness of radiotherapy. Researchers hope their discovery can lead to the development of targeted drugs to enhance cancer treatment.
The University at Buffalo is developing new treatments for ovarian cancer by targeting the apelin receptor. Ovarian cancer cells rely on lipids for energy and survival, making this a promising therapeutic target.
Researchers are refining COBRA, a repair robot inspired by snakes, for medical use in throat cancer and injury surgery. The robot offers more dexterity, accuracy, and high-definition views for surgical teams.
A recent study found that an artificial intelligence-based system improved providers' assessments of bladder cancer patients' response to chemotherapy. The AI tool helped doctors from different specialties and experience levels make more accurate diagnoses, with those in academia showing the greatest gains.
The Endocrine Society's scientific statement highlights the potential of extracellular vesicles in diagnosing and monitoring endocrine-related conditions, including cancer. These tiny vesicles may also serve as biomarkers for high blood pressure and have therapeutic roles.
A recent study published in Neuro-Oncology found that genomic profiling led to more aggressive patient management resulting in improved clinical outcomes compared to traditional biologically matched historical cohorts.
A large-scale analysis of over 12,000 cancers identifies new, rare mutational signatures that can enhance personalized cancer treatments and diagnoses. The study reveals a complex landscape of genetic mutations in cancer genomes.
A novel pancreatic carcinogenesis model in wild-type rats was established using the pancreas-targeted selective hydrodynamic gene delivery method. The KRAS G12D-induced lesions showed malignant transformation and developed into pancreatic ductal adenocarcinoma within five weeks.
A new study reveals a gene called KLF4 that normally suppresses tumor formation but is reprogrammed in acute promyelocytic leukemia, an aggressive type of blood cancer. Overexpressing KLF4 can suppress the growth of cancerous cells and reverse the effects of the disease.
The ESMO Breast Cancer Congress 2022 event will present more than 200 studies on various aspects of breast cancer, including new treatments and innovative clinical practices. The congress will be held onsite in Berlin, Germany, and online, offering a platform for breast cancer specialists to share knowledge and improve patient outcomes.
Researchers have shed light on how immune checkpoint protein LAG3 modulates T cell activity, providing crucial information for the development of new LAG3-blocking therapies. The study found that LAG3 suppresses T cell activation by disrupting coreceptor-Lck association, even in the absence of MHC Class II molecules.
A UCLA-led team has created a roadmap tracing each step in human blood stem cell development, providing a blueprint for producing fully functional blood stem cells. The map could help expand treatment options for blood cancers and inherited disorders.
Researchers have discovered that blood cancer cells steal membranes from immune cells like Natural Killer cells through a process called trogocytosis. This process allows the cancer cells to put the NK cells to sleep, shutting down their anti-cancer activity. The study also sheds light on how PD-1 inhibitors can be used to 'wake up' th...
New research found that 62% of tinted sunscreens have only one shade option, with tone compatibility being the most important criterion. The study suggests that the beauty industry and dermatologic field need to improve diversity and offer more options for tinted sunscreen formulations tailored to people with skin of color.
Researchers discovered a biomarker, S100A9, that correlates with radiotherapy response in brain cancer patients. A new drug, RAGE inhibitor, can reverse resistance to radiotherapy by targeting this mechanism.
Researchers developed a virus that infects cancer cells, killing them while sending signals to nearby uninfected cells for viral attack. This approach shrinks tumors and enhances cancer-killing efficacy in various models, including pancreatic and ovarian cancers.
Patients with mild to moderate kidney disease and kidney transplant recipients had a higher risk of cancer. They also faced a higher risk of dying from cancer, particularly from cancers such as bladder, kidney, and multiple myeloma, compared to those with normal kidney function.
Researchers found a steady decline in annual mammography use by breast cancer survivors between 2009 and 2016, with the largest decrease seen among younger patients. The study highlights the importance of reinforcing the significance of annual mammograms for breast cancer survivors.
Scientists at the University of Bath have developed a new technique called Transcription Block Survival (TBS) to accelerate the discovery of cancer-fighting drugs. TBS identifies molecules that can shut down dangerous proteins before they wreak havoc, by blocking their interaction with cell DNA.
Researchers at UC Irvine and IIT develop ALY101, a compound that blocks protein-protein interactions crucial for cancer and rare disease progression. The findings validate a new approach to structure-based drug design, with potential applications in monotherapy or combination regimens.
A recent analysis found that more than half (59%) of cancer survivors and patients experience at least a moderate level of fear of cancer recurrence. Younger people and women are disproportionately affected. Researchers emphasize the need for tailored interventions to address this common concern.
Researchers have discovered 23 proteins in breast milk that could indicate breast cancer, paving the way for a potential blood test. The study's findings, if confirmed, may enable earlier diagnosis and improve survival rates.
A recent study found that cancer treatment side effects significantly affect patients' and caregivers' eating habits, food preferences, and overall well-being. The research team identified six themes, including managing symptoms, losing taste, and caregiver burden.
Researchers will present breakthroughs in tumor immunology, cancer drug resistance, and early detection methods. The AACR Annual Meeting features a diverse range of studies on various aspects of cancer research.
A study in rats suggests that vitamin C supplementation can help preserve skeletal muscle after doxorubicin therapy, reducing oxidative stress and inflammation. The findings suggest vitamin C may represent a promising opportunity to reduce some of the drug's most debilitating side effects.
A new study suggests that cardamonin, a compound from the cardamom spice, can kill triple-negative breast cancer cells and reduce PD-L1 expression. The findings hold promise for improving cancer therapy without severe side effects.
A new study found that exercising before developing cancer reduced tumor growth and cachexia symptoms in mice. Regular exercise improved cardiac structure and function, and helped slow tumor growth even after cancer was induced.
A study analyzing blood samples from premenopausal women with breast cancer found high levels of inflammatory markers and low antioxidant levels. These findings may reveal a new diagnostic tool for the disease, with implications for identifying early stages and improving treatment outcomes.
The study reveals a narrowing gap between cancer profiles in China and the USA, with converging trends in lung, breast, and colorectal cancers. China's cancer burden is expected to rise, while the US has seen reduced rates since the 1990s due to effective prevention strategies.
The NCCN Annual Conference focuses on the cancer patient journey, featuring state-of-the-art practice algorithms, updates to clinical guidelines, and new therapies. Leading experts present treatment recommendations for various cancer types, including breast, colorectal, and lung cancer.
Research at Universidad Complutense de Madrid found that tumour cells from childhood acute lymphoblastic leukaemia (ALL) can hide in the subventricular neurogenic niche, causing relapses and preventing new neurone generation. This discovery may explain cognitive and sensory alterations in ALL survivors.
Researchers at Okayama University have created a new method to kill cancer cells using light-activated protein AR3, reducing the risk of adverse reactions. The approach uses green light to trigger apoptosis in targeted cells, offering a promising alternative to conventional treatments.
A study published in eLife suggests that accelerated epigenetic age acceleration may increase the risk of bowel cancer. Biological age measured by an epigenetic clock was found to be associated with a 12% increased risk of bowel cancer, particularly colon cancer.
A study published in JAMA Network Open found that Black patients with cancer faced significantly poorer COVID-19 outcomes, including higher hospitalization rates and death tolls. Structural racism in healthcare systems is believed to be a key factor contributing to these disparities.
A new study by University of Southampton researchers found that a third COVID-19 vaccination improves immune responses in blood cancer patients. The study showed that 92% of patients without recent anti-CD20 treatment had improved antibody responses after the third dose.
This year's Experimental Biology 2022 meeting features groundbreaking studies on COVID-19 vaccine-associated symptoms in non-menstruating people, a plant compound showing promise for alleviating food allergies, and the potential of omega-3s to boost immunotherapy's cancer-fighting power. Researchers also explore the safety of using CBD...
A Spanish national registry study found that over half of diagnosed lung cancer patients undergo biomarker testing, with a significant increase over the last five years. Nearly half of patients with positive test results received targeted treatment.
Researchers at ChristianaCare's Gene Editing Institute describe a new process for evaluating the impacts of gene edits that alter rather than completely disabling DNA code. The study validates the safety and efficacy of their novel approach for using CRISPR to improve lung cancer treatments.
Columbia University researchers have engineered a microbial encapsulation system that temporarily hides therapeutic bacteria from immune systems, allowing them to deliver drugs to tumors and kill cancer cells in mice. The system, called iCAP, controls the bacteria's surface by manipulating gene circuits.
The European Lung Cancer Congress 2022 focused on the latest advancements in lung cancer treatment, including personalized strategies for better patient care. The congress also explored emerging therapies and molecular sub-types to enhance precision medicine.
The National Comprehensive Cancer Network has published new consensus recommendations to improve the safety and efficiency of research studies involving investigational drugs. The recommendations focus on seven areas, including pharmacy workflows and collaboration with sponsors.
A new study published in Annals of Internal Medicine found that state laws regulating opioid prescriptions had no effect on prescribing patterns for commercially insured adults with chronic non-cancer pain. The study suggests that declines in opioid prescribing may be driven by shifting clinical guidance or other factors.
Research found a significant drop in new cancer diagnoses during the COVID-19 pandemic, particularly for screening cancers like breast, cervical, and colorectal cancer. The study estimates around 12,600 cancers went undetected between March 2020 and September 2020.
Researchers at Ludwig Stanford University have solved the structure of a key protein involved in immune cell signaling and blood cancers. The study reveals how mutant versions of this protein lead to continuous growth signals, driving cell proliferation and blood cancers.
Scientists developed a novel approach to securely share and analyze genomic data, enabling a more nuanced understanding of heritable diseases like cancer. This 'federated analysis' method allows researchers to analyze large amounts of genomic and clinical data without compromising patient privacy.
Researchers at UCSF develop a new cancer treatment that targets RAS-mutated tumors by exploiting their high levels of ferrous iron. The treatment, TRX-cobimetinib, is more effective and tolerable than current treatments like cobimetinib, which can cause serious side effects in normal tissues.
A novel radioligand therapy has been shown to increase progression-free survival (PFS) and overall survival (OS) of metastatic castration-resistant prostate cancer (mCRPC) patients. Ninety-one percent of patients experienced a greater than 50% reduction in PSA values after treatment, with a median PFS of 22 months.
A research team has devised a novel strategy to overcome chemotherapy resistance in cancer by boosting the pro-apoptotic BAX protein and targeting its inhibitor, BCL-XL. The two-drug combination achieved significant success against apoptosis-resistant human tumor cell lines and xenograft models, with minimal side effects.
Researchers at the Salk Institute successfully reversed aging signs in middle-aged and elderly mice using a cellular rejuvenation approach. The treatment, which involves reprogramming cells with four specific molecules, restored youthful epigenetic patterns and improved tissue function without increasing cancer risk.
A survey of young adult cancer survivors found that crowdfunding provides relief in paying bills, but also involves compromises such as revealing personal health details and feeling uncomfortable asking for help. The study suggests that crowdfunding could be exacerbating racial and economic disparities.
Researchers created implantable beads that produce high concentrations of interleukin-2, a natural compound activating white blood cells to fight cancer. The treatment eradicated ovarian and colorectal cancer in mice within six days, paving the way for human clinical trials later this year.
Researchers found an association between certain cancers and Guillain-Barré syndrome, with people diagnosed with lymphomas, blood cancers, lung, prostate, or breast cancer having a higher risk. The study suggests that unidentified factors in several types of cancer may contribute to this increased risk.
Researchers will compare proton, carbon and electron radiotherapy to protect normal tissues from harm while controlling solid tumors of the gastrointestinal tract, lungs, soft tissues throughout the body, and bones. The goal is to develop a more effective treatment with shorter duration and frequency.
The study found that White people are more than twice as likely to get some types of cancer, including melanoma skin cancer and oesophageal bladder cancers, compared to Black, Asian or Mixed ethnic backgrounds. Black people are also more likely to get certain types of cancer, such as myeloma and prostate cancer.
A pooled data analysis found that between 30 and 60 minutes of muscle strengthening activity per week is associated with a 10-17% lower risk of death from any cause. The J-shaped curve showed no conclusive evidence that more than an hour of this activity reduces the risk further.
Researchers identified USP17 as a deubiquitinating enzyme regulating c-Myc levels and controlling cell proliferation and glycolysis. The study suggests USP17 as a potential therapeutic target for cancer treatment.
A study published in Nature Cancer has found that tissue damage caused by radiation can facilitate the spread of cancer, with neutrophils playing a key role. The researchers used mice to test the effect of high doses of radiation on healthy lung tissue and found that secondary tumours formed more easily in damaged lungs.
Researchers at UNC Lineberger Comprehensive Cancer Center have developed a new therapeutic approach using a small-molecule inhibitor of the chromatin-modulatory enzyme EZH2 to target aggressive cancer cells. The treatment also targets cMyc, a prominent cancer-causing factor, and shows profound tumor killing effects.
Eating meat five times or less per week is associated with a lower overall cancer risk, according to a study published in BMC Medicine. Participants who ate meat five or less times per week had a 2% lower cancer risk compared to those who ate meat more than five times per week.
Researchers at MDI Biological Laboratory discovered that age-related chronic inflammation is caused by disruption of chromatin architecture. This leads to misexpression of genes lacking CpG islands, resulting in inflammation and loss of cellular function. The findings provide a unifying theory for the age-related degenerative diseases.